WO2006114273A2 - Vaccine - Google Patents
Vaccine Download PDFInfo
- Publication number
- WO2006114273A2 WO2006114273A2 PCT/EP2006/003809 EP2006003809W WO2006114273A2 WO 2006114273 A2 WO2006114273 A2 WO 2006114273A2 EP 2006003809 W EP2006003809 W EP 2006003809W WO 2006114273 A2 WO2006114273 A2 WO 2006114273A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- vaccine
- protein
- type
- immunogenic fragment
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 195
- 208000015181 infectious disease Diseases 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000002245 particle Substances 0.000 claims abstract description 15
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 70
- 230000002163 immunogen Effects 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 39
- 231100000590 oncogenic Toxicity 0.000 claims description 28
- 230000002246 oncogenic effect Effects 0.000 claims description 28
- 230000002265 prevention Effects 0.000 claims description 27
- 239000002671 adjuvant Substances 0.000 claims description 26
- 230000005856 abnormality Effects 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 230000002380 cytological effect Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000003902 lesion Effects 0.000 claims description 13
- 208000037581 Persistent Infection Diseases 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 8
- 159000000013 aluminium salts Chemical group 0.000 claims description 6
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- 229960002566 papillomavirus vaccine Drugs 0.000 claims description 5
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 abstract description 296
- 241000341655 Human papillomavirus type 16 Species 0.000 abstract description 23
- 238000002649 immunization Methods 0.000 abstract description 4
- 230000003053 immunization Effects 0.000 abstract description 4
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 55
- 238000004458 analytical method Methods 0.000 description 20
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 18
- 208000009608 Papillomavirus Infections Diseases 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 17
- 239000000902 placebo Substances 0.000 description 17
- 150000007949 saponins Chemical class 0.000 description 17
- 229930182490 saponin Natural products 0.000 description 16
- 235000017709 saponins Nutrition 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 206010008342 Cervix carcinoma Diseases 0.000 description 12
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 12
- 201000010881 cervical cancer Diseases 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000002085 persistent effect Effects 0.000 description 9
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 206010008263 Cervical dysplasia Diseases 0.000 description 7
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000009595 pap smear Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 3
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 101150070189 CIN3 gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000701828 Human papillomavirus type 11 Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 101150005988 cin2 gene Proteins 0.000 description 2
- 238000002573 colposcopy Methods 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102220047090 rs6152 Human genes 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 201000007490 Adenocarcinoma in Situ Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 229940033278 HPV-16/18 vaccine Drugs 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010042365 Virus-Like Particle Vaccines Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001399 aluminium compounds Chemical class 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000021145 human papilloma virus infection Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Definitions
- the present invention relates to human papillomavirus (HPV) vaccines.
- Papillomaviruses are small DNA tumour viruses, which are highly species specific. So far, over 100 individual human papillomavirus (HPV) genotypes have been described. HPVs are generally specific either for the skin (e.g. HPV-I and -2) or mucosal surfaces (e.g. HPV-6 and -11) and usually cause benign tumours (warts) that persist for several months or years. Such benign tumours may be distressing for the individuals concerned but tend not to be life threatening, with a few exceptions.
- HPVs human papillomavirus
- HPVs are also associated with cancers, known as oncogenic HPV types.
- the strongest positive association between an HPV and human cancer is that which exists between HPV- 16 and HPV- 18 and cervical carcinoma. Cervical cancer is the most common malignancy in developing countries, with about 500,000 new cases occurring in the world each year.
- HPV types which can cause cancer are types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 (referred to as "oncogenic-HPV types").
- Types 16 and 18 are those which have the highest association with cervical cancer.
- Types 31 and 45 are the types with the next highest association with a cancer risk (Munoz N, Bosch FX, de Sanjose S et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. N Engl J Med 2003; 348: 518-27.)
- VLPs HPV virus like particles
- Animal studies have shown that VLPs produce no cross protection against infection for other HPV types - see, for example Suzich, J.
- HPV 16, 18 VLP vaccine can provide cross protection against infection by HPV types other than 16 and 18. Statistically significant protection was observed against certain groups of HPV types. However, the level of cross protection against individual types within groups was not disclosed.
- the present invention relates to a multivalent HPV vaccine, the vaccine comprising an Ll protein or immunogenic fragment thereof from at least 3 different oncogenic HPV types, those types including HPV 16 and HPV 18, wherein the vaccine does not comprise an Ll protein or immunogenic fragment thereof from an HPV type selected from the list consisting of HPV 31, HPV 45, HPV 52 or any combination thereof.
- the present invention further relates to use of a composition comprising an Ll protein or immunogenic fragment thereof from HPV 16 and HPV 18 in the manufacture of a medicament for prevention of infection and/or disease by one or more of the group consisting of HPV 31, HPV 45 and HPV 52.
- the present invention further relates to use of a composition comprising an Ll protein or immunogenic fragment thereof from HPV 16 and HPV 18 in the manufacture of a medicament for prevention of cyto logical abnormalities, and/or reduction of the frequency of c ytological abnormalities, and/or prevention of CIN lesions (ASCUS, CEN 1, CIN 2, CIN , cervical cancer) in an individual, the abnormalities or lesions caused by at least one HPV type other than HPV 16 or HPV 18, suitably being caused by HPV type 31, or 45, or 52, or a combination thereof.
- the invention further relates to a method of prevention and/or treatment of HPV infection and/or disease, the method comprising delivering to an individual in need thereof an effective amount of a composition comprising an Ll protein or immunogenic fragment thereof from at least 3 different oncogenic HPV types, those types including HPV 16 and HPV 18, wherein the vaccine does not comprise an Ll protein or immunogenic fragment thereof from an HPV type selected from the list consisting of HPV 31, HPV 45, HPV 52 or any combination thereof.
- the invention further relates to use of a multivalent composition in the manufacture of a medicament for the prevention and/or treatment of HPV infection and/or disease, the multivalent composition comprising an Ll protein or immunogenic fragment thereof from at least 3 different oncogenic HPV types, those types including HPV 16 and HPV 18, wherein the vaccine does not comprise an Ll protein or immunogenic fragment thereof from an HPV type selected from the list consisting of HPV 31, HPV 45, HPV 52 or any combination thereof, and wherein the medicament provides protection against infection and/or disease caused by the omitted HPV type.
- the invention also relates to a method for manufacture of a vaccine, the method comprising combining an Ll protein or immunogenic fragment thereof from at least 3 different oncogenic HPV types, those types including types HPV 16 and HPV 18, wherein the vaccine does not comprise an Ll protein or immunogenic fragment thereof from an HPV type selected from the list consisting of HPV 31, HPV 45, HPV 52 or any combination thereof.
- Cross protection may be considered as the protection afforded by a vaccine containing one HPV type against infection (incident or persistent) and/or disease caused by a different HPV type.
- Cross protection may be assessed by considering the vaccine efficacy (V.E.), wherein the V.E. is the % improvement in protection against infection or disease by the vaccine compared to a placebo group for a given type. Infection may be incident or persistent infection.
- Disease may be abnormal cytology, ASCUS, CINl, CIN2, CIN3 or cervical cancer related to HPV infection. Infection may be assessed by PCR, for example. Disease may be assessed by, for example, histological examination or analysis of biomarkers such as pi 6.
- HPV 16 and HPV 18 Ll containing vaccines against certain other HPV types allows Ll components from these HPV types to be omitted from a vaccine comprising HPV 16 and HPV 18 while still providing a vaccine which provides some protection against incident and/or persistent infection and/or disease related to those omitted types.
- HPV types 16 found in 53.5% of cervical cancer
- types 45 (6.7%) and 31 (2.9%) are the next most significant in terms of their frequency in cervical cancers (Munoz et al. supra).
- HPV 33 (2.6%) is next, followed by HPV 52 (2.3%).
- types 31 and 45 would generally be included by the skilled person after types 16 and 18 from a statistical perspective.
- HPV types potentially allows inclusion of Ll protein from other HPV types, or indeed antigens from other viruses or pathogens, into a vaccine in a scenario where the total amount of antigen in a vaccine may be limited, for example by physical, chemical, regulatory or other constraints.
- HPV types include oncogenic HPV types such as HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
- the present invention relates to a multivalent HPV vaccine, the vaccine comprising an Ll protein or immunogenic fragment thereof from at least 3 different oncogenic HPV types, those types including HPV 16 and HPV 18, wherein the vaccine does not comprise an Ll protein or immunogenic fragment thereof from an HPV type selected from the list consisting of HPV 31, HPV 45, HPV 52 or any combination thereof.
- the vaccine does not contain an Ll protein or immunogenic fragment thereof from HPV 31.
- the vaccine is capable of providing protection against incident and /or persistent HPV infection by HPV 31.
- the vaccine of the invention does not contain an Ll protein or immunogenic fragment thereof from HPV 45. In one aspect of the invention the vaccine is capable of providing protection against incident and /or persistent HPV infection by HPV 45. In one aspect of the invention the vaccine does not contain an Ll protein or immunogenic fragment thereof from HPV 52.
- the vaccine is capable of providing protection against incident and /or persistent HPV infection by HPV 52. In one aspect of the invention the vaccine of the invention does not contain an
- Ll protein or immunogenic fragment thereof from HPV 31 and 45 Ll protein or immunogenic fragment thereof from HPV 31 and 45.
- the vaccine is capable of providing protection against incident and /or persistent HPV infection by both HPV 31 and 45.
- the vaccine does not contain an Ll protein or immunogenic fragment thereof from HPV 31 and 52.
- the vaccine is capable of providing protection against incident and /or persistent HPV infection by both HPV 31 and 52.
- the vaccine of the invention does not contain an Ll protein or immunogenic fragment thereof from HPV 45 and 52. hi one aspect of the invention the vaccine is capable of providing protection against incident and /or persistent HPV infection by both HPV 52 and 45.
- the vaccine is capable of providing protection against incident and /or persistent HPV infection by HPV 31 and HPV 45 and HPV52.
- the vaccine is capable of protection against persistent infection.
- the vaccine is capable of protection against incident infection.
- Example 1 Incident and persistent cervical infection are defined in Example 1.
- a vaccine comprising HPV 16 Ll and HPV 18 Ll proteins (for example, as described in example 1) provides protection against cytological abnormalities caused by certain other oncogenic HPV types such as HPV 52, and is significantly protective with respect to such abnormalities caused by a group of HPV high risk types (defined as 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Cytological abnormalities are suitably detected by the well known Pap smear technique.
- the invention further relates to use of a combination of an Ll protein or immunogenic fragment thereof from HPV 16 and HPV 18 in the preparation of a composition for the prevention of cytological abnormalities or reduction of the frequency of cytological abnormalities in an individual caused by other (non HPV 16, HPV 18) HPV types, suitably oncogenic HPV types, and in the prevention of histologically-confirmed CIN lesions (CEST 1, CIN 2, CESf 3) and cervical cancer associated with infection by HPV types which are not HPV 16 or 18. Said use is in addition to the prevention or reduction of such events caused by the HPV types in the vaccine, HPV 16 and 18.
- the prevention of cytological abnormalities, reduction of the frequency of cytological abnormalities or prevention of histological-confirmed CEST lesions is prevention against those abnormalities or lesions caused by types not included in the combination, suitably selected from the list of HPV 31, HPV 45 and HPV 52, or is prevention against those abnormalities or lesions caused by the group of 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Said use is in addition to the prevention or reduction of such events caused by the HPV types in the vaccine, HPV 16 and 18.
- composition comprising HPV 16 and HPV 18 for use as above is the multivalent HPV vaccine of the invention, the vaccine comprising an Ll protein or immunogenic fragment thereof from at least 3 different oncogenic HPV types, those types including HPV 16 and HPV 18, wherein the vaccine does not comprise an Ll protein or immunogenic fragment thereof from an HPV type selected from the list consisting of HPV 31, HPV 45, HPV 52 or any combination thereof.
- the vaccine of the invention comprises Ll or immunogenic fragment from
- HPV 16, HPV 18 and at least one other oncogenic HPV type are those types associated with a risk of cervical cancer and those oncogenic types that might be included in the vaccine of the invention in addition to HPV 16 and HPV 18 include, but are not limited to, HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, with the proviso that the vaccine does not comprise all of HPV 31, 45 and 52.
- the vaccine of the invention suitably comprises an HPV 33 Ll protein or immunogenic fragment thereof.
- the vaccine of the invention suitably comprises an HPV 58 Ll protein or immunogenic fragment thereof.
- the vaccine of the invention suitably comprises an HPV 59 Ll protein or immunogenic fragment thereof.
- the vaccine of the invention suitably comprises an HPV 16 Ll protein or immunogenic fragment thereof, HPV 18 Ll protein or immunogenic fragment thereof, HPV 33 Ll protein or immunogenic fragment thereof and HPV 58 Ll protein or immunogenic fragment thereof.
- Ll proteins or protein fragments from additional HPV types can be included in the vaccine of the invention, such as skin types (in particular HPV 5 and 8) and types associated with genital warts, such as HPV 6 and 11. Types 6 and 11 are not considered oncogenic types herein.
- the vaccine may include an HPV early antigen, for example an antigen selected from the list consisting of HPV El, E2, E3, E4, E5, E6, E7, or E8.
- the vaccine may lack an HPV early antigen, for example an antigen selected from the list consisting of HPV El, E2, E3, E4, E5, E6, E7, or E8.
- the vaccine of the invention is trivalent (contains an HPV Ll or fragment thereof from 3 different oncogenic HPV types).
- the vaccine is tetravalent.
- the vaccine is pentavalent.
- the vaccine is heptavalent.
- the vaccine is septavalent.
- the vaccine is octavalent. Higher order valancies are also contemplated herein.
- the vaccine is at least tetravalent, pentavalent, heptavalent, septavalent or octavalent with respect to oncogenic HPV types.
- the combination of HPV components within the vaccine does not significantly impact the immunogenicity of any one HPV component.
- there is no biologically relevant interference between HPV antigens in the combination of the invention such that the combined vaccine of the invention is able to offer effective protection against infection or disease caused by each HPV genotype represented in the vaccine.
- the immune response against a given HPV type in the combination is at least 50 % of the immune response of that same HPV type when measured individually, preferably 100% or substantially 100%.
- the combined vaccine of the invention preferably stimulates an immune response which is at least 50% of that provided by a combined HPV 16 / HPV 18 vaccine.
- the immune response generated by the vaccine of the invention is at a level in which the protective effect of each HPV type is still seen.
- the immune response may suitably be measured, for example, by antibody responses, in either preclinical or human experiments. Measurement of antibody responses is well known in the art, and disclosed in (for example) WO03/077942.
- the invention relates to use of a composition comprising HPV 16 and HPV 18 Ll protein, or immunogenic fragment thereof, in the manufacture of a medicament for prevention of infection by HPV 31.
- the invention further relates to use of a composition comprising HPV 16 and
- the invention further relates to use of a composition comprising HPV 16 and
- HPV 18 Ll protein, or immunogenic fragment thereof in the manufacture of a medicament for prevention of infection by HPV 52.
- the invention relates to use of a vaccine comprising HPV 16 Ll proteins, or immunogenic fragment thereof, in the preparation of a medicament for the prevention of infection and/or disease caused by HPV 31, or HPV 52, or any combination thereof.
- the invention relates to use of a vaccine comprising HPV 18 Ll proteins, or immunogenic fragment thereof, in the preparation of a medicament for the prevention of infection and/or disease caused by HPV 45.
- the composition for said use may lack an antigenic component from the HPV type for which cross protection is provided.
- the composition for said use may comprise such an antigenic component, e.g. the Ll protein or fragment thereof from said cross protected type, hi the latter case the use of the composition comprising
- HPV 16 and HPV 18 Ll protein, or immunogenic fragment thereof provides both cross protection (e.g. against HPV 31, 45 and 52) and homologous protection (e.g. against
- composition in one aspect is a multivalent composition comprising Ll proteins or immunogenic fragments thereof from HPV 16, HPV 18 and at least one other oncogenic HPV type, wherein an Ll protein or immunogenic fragment thereof from one or more HPV types selected from the group consisting of HPV 31, HPV 45, and HPV 52 is omitted from the vaccine and wherein the vaccine provides protection against infection caused by the omitted HPV type.
- suitable immunogenic fragments of HPV Ll include truncations, deletions, substitution, or insertion mutants of Ll .
- Such immunogenic fragments are suitably capable of raising an immune response (if necessary, when adjuvanted), said immune response being capable of recognising an Ll protein such as a virus like particle, from the HPV type from which the Ll protein was derived.
- a suitable immunogenic fragment of HPV 16 is capable of cross protection against at least one of HPV 31 and HPV 52, and in an aspect of the invention, capable of cross protection against both.
- a suitable immunogenic fragment of HPV 18 is capable of cross protection against HPV 45.
- Cross protection obtainable by immunogenic fragments of HPV 16 and/or HPV 18 can be assessed by trials in humans, for example as outlined in Example 1.
- different vaccines according to the present invention can be tested using standard techniques, for example as in Example 1 , or in standard preclinical models, to confirm that the vaccine is immunogenic.
- Suitable immunogenic Ll fragments include truncated Ll proteins.
- the truncation removes a nuclear localisation signal.
- the truncation is a C terminal truncation.
- the C terminal truncation removes fewer than 50 amino acids, such as fewer than 40 amino acids.
- the Ll is from HPV 16 then in another aspect the C terminal truncation removes 34 amino acids from HPV 16 Ll .
- the Ll is from HPV 18 then in a further aspect the C terminal truncation removes 35 amino acids from HPV 18 Ll.
- Truncated Ll Proteins are described in US 6,060,324, US 6,361,778, and US 6,599,508 incorporated herein by reference.
- the HPV 16 amino acid sequence is the following sequence: (SEQ ED NO: 1)
- the invention relates to virus like particles consisting only of HPV 16 Ll having the amino sequence above, and to compositions containing such VLPs.
- HPV 16 sequence may also be that disclosed in WO9405792 or US6649167, for example, suitably truncated. Suitable truncates are truncated at a position equivalent to that shown above, as assessed by sequence comparison.
- HPV 18 amino acid sequence is the following sequence: (SEQ ID NO: 2)
- the invention relates to virus like particles consisting only of HPV 18
- HPV 18 sequence is disclosed in WO9629413, which may be suitably truncated. Suitable truncates are truncated at a position equivalent to that shown above, as assessed by sequence comparison.
- Other HPV 16 and HPV 18 sequences are well known in the art and may be suitable for use in the present invention.
- Suitable truncations of HPV 31, HPV 45 and HPV 52 may also be made, suitably removing equivalent C terminal portions of the Ll protein to those described above as assessed by sequence alignment.
- Truncated Ll proteins are disclosed in, for example, WO9611272 and US6066324, herein incorporated by reference.
- the Ll protein or fragment of the invention may optionally be in the form of a fusion protein, such as the fusion of the Ll protein with L2 or an early protein.
- the HPV Ll protein is suitably in the form of a capsomer or virus like particle
- HPV VLPs may be used in the present invention.
- HPV VLPs and methods for the production of VLPs are well known in the art.
- VLPs typically are constructed from the Ll and optionally L2 structural proteins of the virus, see for example WO9420137, US5985610, W09611272. US6599508B1, US6361778B1, EP 595935. Any suitable HPV VLP may be used in the present invention which provides cross protection, such as an Ll or Ll + L2 VLP.
- the VLP is an Ll -only VLP.
- the vaccine comprises HPV 16 and HPV 18 Ll only VLPs, suitably in combination with an Ll VLP selected from HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, with the proviso that the vaccine does not comprise VLPs from all of HPV 31, 45 and 52.
- VLP formation can be assessed by standard techniques such as, for example, electron microscopy and dynamic laser light scattering.
- the VLP may comprise full length Ll protein.
- the Ll protein used to form the VLP is a truncated Ll protein, as described above.
- VLPs may be made in any suitable cell substrate such as yeast cells or insect cells e.g. baculovirus cells, and techniques for preparation of VLPs are well known in the art, such as WO9913056, US 6416945B1 , US 6261765B1 and US6245568, and references therein, the entire contents of which are hereby incorporated by reference.
- VLPS are suitably made by disassembly and reassembly techniques, which can provide for more stable and/or homogeneous papillomavirus VLPs. For example, McCarthy et al, 1998 "Quantitative Disassembly and Reassembly of Human Papillomavirus Type 11 Virus like Particles in Vitro" J.
- Virology 72(1):33-41 describes the disassembly and reassembly of recombinant Ll HPV 11 VLPs purified from insect cells in order to obtain a homogeneous preparation of VLPs.
- WO9913056 and US6245568 also describe disassembly/reassembly processes for making HPV VLPs.
- HPV VLPS are made as described WO9913056 or US6245568.
- HPV Ll the invention may be combined with an adjuvant or imunostimulant such as, but not limited to, detoxified lipid A from any source and non- toxic derivatives of lipid A, saponins and other reagents capable of stimulating a THl type response.
- an adjuvant or imunostimulant such as, but not limited to, detoxified lipid A from any source and non- toxic derivatives of lipid A, saponins and other reagents capable of stimulating a THl type response.
- enterobacterial lipopolysaccharide is a potent stimulator of the immune system, although its use in adjuvants has been curtailed by its toxic effects.
- LPS enterobacterial lipopolysaccharide
- MPL monophosphoryl lipid A
- a further detoxified version of MPL results from the removal of the acyl chain from the 3-position of the disaccharide backbone, and is called 3-O-Deacylated monophosphoryl lipid A (3D-MPL). It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3-0-deacylated variants thereof.
- a suitable form of 3D-MPL is in the form of an emulsion having a small particle size less than 0.2 ⁇ m in diameter, and its method of manufacture is disclosed in WO 94/21292.
- Aqueous formulations comprising monophosphoryl lipid A and a surfactant have been described in WO9843670A2.
- the bacterial lipopolysaccharide derived adjuvants to be formulated in the compositions of the present invention may be purified and processed from bacterial sources, or alternatively they may be synthetic.
- purified monophosphoryl lipid A is described in Ribi et al 1986 (supra), and 3-O-Deacylated monophosphoryl or diphosphoryl lipid A derived from Salmonella sp.
- the LPS derivatives that may be used in the present invention are those immunostimulants that are similar in structure to that of LPS or MPL or 3D- MPL.
- the LPS derivatives may be an acylated monosaccharide, which is a sub-portion to the above structure of MPL.
- Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. Phytomedicine vol 2 pp 363- 386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins. Saponins are known as adjuvants in vaccines for systemic administration.
- ICOMS Immune Stimulating Complexes
- Quil A fractions of Quil A are haemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 Bl; WO 96/11711; WO 96/33739).
- the haemolytic saponins QS21 and QS 17 HPLC purified fractions of Quil A have been described as potent systemic adjuvants, and the method of their production is disclosed in US Patent No.5,057,540 and EP 0 362 279 Bl.
- saponins which have been used in systemic vaccination studies include those derived from other plant species such as Gypsophila and Saponaria (Bomford et al., Vaccine, 10(9):572-577, 1992).
- An enhanced system involves the combination of a non-toxic lipid A derivative and a saponin derivative particularly the combination of QS21 and 3 D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.
- a vaccine adjuvanted with detoxified lipid A or a non-toxic derivative of lipid A more suitably adjuvanted with a monophosphoryl lipid A or derivative thereof.
- the vaccine additionally comprises a saponin, for example QS21.
- the vaccine formulation comprises an oil in water emulsion.
- the present invention also provides a method for producing a vaccine formulation comprising mixing an Ll peptide of the present invention together with a pharmaceutically acceptable excipient, such as 3D-MPL.
- a formulation comprises 3D-MPL, Triton X-100, Tween 80 and sodium deoxycholate, which may be combined with an L2 antigen preparation to provide a suitable vaccine.
- the vaccine comprises a vesicular adjuvant formulation comprising cholesterol, a saponin and an LPS derivative
- the adjuvant formulation suitably comprises a unilamellar vesicle comprising cholesterol, having a lipid bilayer suitably comprising dioleoyl phosphatidyl choline, wherein the saponin and the LPS derivative are associated with, or embedded within, the lipid bilayer.
- these adjuvant formulations comprise QS21 as the saponin, and 3D-MPL as the LPS derivative, wherein the ratio of QS21:cholesterol is from 1 :1 to 1 :100 weight/weight, and in one aspect, a ratio of 1 :5 weight/weight.
- Such adjuvant formulations are described in EP 0 822 831 B, the disclosure of which is incorporated herein by reference.
- the vaccines of the invention are used in combination with aluminium, and are suitably adsorbed or partially adsorbed onto aluminium adjuvants.
- the adjuvant is an aluminium salt, which may be in combination with 3D MPL, such as aluminium phosphate and 3D MPL. Aluminium hydroxide, optionally in combination with 3D MPL is also suitable.
- the vaccine comprises the combination of HPV VLPs with an aluminium salt or with an aluminium salt + 3D MPL. Aluminium hydroxide is suitable as the aluminium salt.
- the vaccine may also comprise aluminium or an aluminium compound as a stabiliser.
- the adjuvant may be a combination of an oil-in-water emulsion adjuvant and 3D MPL.
- the oil-in-water emulsion comprises a metabolisable oil, a sterol and an emulsifying agent.
- the vaccines of the invention may be provided by any of a variety of routes such as oral delivery (e.g. see WO9961052 A2) , topical, subcutaneous, mucosal
- the vaccine may also be formulated or co-administered with other HPV antigens or non-HPV antigens.
- these non-HPV antigens can provide protection against other diseases, such as sexually transmitted diseases such as herpes simplex virus, EBV, chlamydia and HIV.
- the vaccine comprises gD or a truncate thereof from HSV. In this way the vaccine provides protection against both HPV and HSV.
- the dosage of the vaccine components will vary with the condition, sex, age and weight of the individual, the administration route and HPV of the vaccine.
- the quantity may also be varied with the number of VLP types.
- the delivery is of an amount of vaccine suitable to generate an immunologically protective response.
- each vaccine dose comprises 1-100 ⁇ g of each VLP, in one aspect 5-80 ⁇ g, in another aspect 5- 30 ⁇ g each VLP, in a further aspect 5-20 ⁇ g of each VLP, in a yet further aspect 5 ⁇ g, 6 ⁇ g, lO ⁇ g, 15 ⁇ g or 20 ⁇ g.
- the vaccine can comprise HPV Ll protein components, preferably as virus like particles, in different amounts.
- HPV 16 and HPV 18 VLPs may be provided at a higher dose than other oncogenic types, such as HPV 33 or 58.
- HPV 16 and HPV 18 Ll only VLPs are provided at 20 ⁇ g per dose for human use.
- Other HPV VLPs may be used at a lower dose, such as 15 or 1 O ⁇ g per dose for human use.
- the vaccine is used for the vaccination of adolescent girls aged 10-15, such as 10-13 years. However, older girls above 15 years old and adult women may also be vaccinated.
- the vaccine may also be administered to women following an abnormal pap smear or after surgery following removal of a lesion caused by HPV, or who are seronegative and DNA negative for HPV cancer types.
- the vaccine of the invention may be used in men.
- the vaccine is delivered in a 2 or 3 dose regime, for example in a 0, 1 month regime or 0,1 and 6 month regime respectively.
- the vaccination regime incorporates a booster injection after 5 to 10 years, such as 10 years.
- the vaccine is a liquid vaccine formulation, although the vaccine may be lyophilised and reconstituted prior to administration.
- the vaccines of the invention comprise certain HPV components as laid out above.
- the vaccine consists essentially of, or consists of, said components.
- 'vaccine' refers to a composition that comprises an immunogenic component capable of provoking an immune response in an individual, such as a human, optionally when suitably formulated or adjuvant.
- a vaccine suitably elicits a protective immune response against incident infection, or persistent infection, or cytological abnormality such as ASCUS, CESTI, CIN2 , CIN3, or cervical cancer caused by one or more HPV types.
- the mixture comprised, per 0.5 ml dose, 20 ⁇ g of HPV-16 Ll VLP, 20 ⁇ g of HPV-18 Ll VLP and was adjuvanted with 500 ⁇ g of aluminum hydroxide and 50 ⁇ g of 3D MPL.
- the placebo group was injected with 500 ⁇ g of aluminum hydroxide alone.
- V.E. The vaccine efficacy (V.E.) against certain cancer HPV types was assessed, wherein the V.E. is the % improvement in protection against infection or disease by the vaccine compared to a placebo group.
- Cross protection was assessed by detecting the presence of nucleic acid specific for various oncogenic types in the vaccinees and control group. Detection was carried out using techniques as described in WO03014402, and references therein, particularly for non-specific amplification of HPV DNA and subsequent detection of DNA types using a LiPA system as described in WO 99/14377, and in Kleter et al, [Journal of Clinical Microbiology (1999), 37 (8): 2508-2517], the whole contents of which are herein specifically incorporated by reference.
- Any suitable method can, however, be used for the detection of HPV DNA in a sample, such as type specific PCR using primers specific for each HPV type of interest.
- Suitable primers are known to the skilled person, or can be easily constructed given that the sequences of the oncogenic HPV types are known.
- the primary objective of this study was to assess vaccine efficacy in the prevention of infection with HPV-16, HPV-18, or both (HPV-16/18), between months 6 and 18 in participants who were initially shown to be seronegative for HPV-16/18 by ELISA and negative for HPV-16/18 DNA by PCR.
- Women eligible for the initial phase included healthy women aged 15-25 years, who had had no more than six sexual partners, no history of an abnormal Pap test or ablative or excisional treatment of the cervix, and no ongoing treatment for external condylomata; and who were cytologically negative, seronegative for HPV- 16 and HPV- 18 antibodies by ELISA, and HP V-DNA-negative by PCR for 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) no more than 90 days before study entry.
- Each dose of the bivalent HPV- 16/18 virus-like particle vaccine contained 20 Pg of HPV-16 Ll virus-like particle and 20 Pg of HPV- 18 Ll virus-like particle.
- Each type of virus-like particle was produced on Spodoptera frugiperda Sf-9 and Trichoplusia ni Hi-5 cell substrate with AS04 adjuvant containing 500 Pg aluminum hydroxide and 50 fg 3- deacylated monophosphoryl lipid A (MPL, Corixa, Montana, USA) provided in a monodose vial.
- the placebo contained 500 Pg of aluminum hydroxide per dose, and was identical in appearance to the HPV- 16/18 vaccine.
- Health-care providers obtained cervical specimens with a cervical brush and spatula (washed in PreservCyt, Cytyc Corporation, Boxborough, MA, USA) for cytology and HPV DNA testing at screening and months 6, 12, and 18.
- PreservCyt Cytyc Corporation, Boxborough, MA, USA
- the central histology laboratory made an initial diagnosis from the formalin-fixed tissue specimens for clinical management.
- a panel of three pathologists made a subsequent consensus diagnosis for HPV- 16 and HPV- 18 associated lesions with the CIN system. This consensus diagnosis also included review of the sections taken at the time of microdissection for PCR detection of lesional HPV DNA.
- HPV DNA isolated from the cytology specimen MagneticNaPure Total Nucleic Acid system, Roche Diagnostics, Almere, Netherlands
- cervical biopsy specimen proteinase K extraction
- SPFlO broad-spectrum primers that amplify a 65 bp region of the Ll gene.
- a line probe assay (LiPA Kit HPV INNO LiPA HPV genotyping assay, SPF-IO system version 1, Innogenetics, Gent, Belgium, manufactured by Labo Biomedical Products, Rijswijk, Netherlands) detected 25 HPV genotypes (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, and 74).
- HPV- 16 and HPV- 18 PCR Any specimen that was positive by DNA enzyme immunoassay was tested by type-specific HPV- 16 and HPV- 18 PCR.
- HPV- 16 type-specific PCR primers amplified a 92 bp segment of the E6/E7 gene and HPV-18 type-specific PCR primers amplified a 126 bp segment of the Ll gene.
- MF Baay, WG Quint, J Koudstaal et ah Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 34 (1996), pp.
- HPV-DNA test results were concealed from investigators during the study and cyto logical and histological diagnoses were only revealed for clinical management purposes. Analyses included HPV- 16/18 DNA results for cervical specimens and combined cervical and self-obtained cervicovaginal specimens.
- the intention-to-treat and according-to-protocol cohorts are shown in the figure, in which the reasons for exclusion from analyses are listed in rank order; women who met more than one exclusion criterion were only counted once according to the highest ranking criterion.
- Vaccine efficacy was defined as 1 minus the ratio between these two proportions; 95% CIs measured the precision of the efficacy estimates, p values were calculated with the two-sided Fisher's exact test. Corresponding rates were expressed as the numbers of cases with the outcome divided by the numbers of participants at risk.
- the according-to-protocol 18-month cohort included enrolled women who received three scheduled doses of vaccine and complied with the protocol as described in the figure.
- Immunogenicity was assessed in a subset of the according-to-protocol safety cohort, which included women with serology results at months 0, 7, and 18, who received all three doses of study vaccine or placebo according to schedule, complied with the blood sampling schedule, and did not become positive for HPV-16/18-DNA during the trial. Seropositivity rates between the vaccine and placebo groups were compared with Fisher's exact test (p ⁇ 0-001 judged significant). Geometric mean titres were compared with ANOVA and Kruskal-Wallis test. Block randomisation and statistical analyses were done with SAS version 8.2 (SAS Institute, Cary, North Carolina).
- Table B is a midpoint analysis with data taken from all patients at the timepoint at which at least 50% of the cohort were 18 months after their first vaccination.
- Table C gives the final results, all data being from subjects at 18 months post first vaccination (month 0). In the ATP group all patients received 3 doses of vaccine at 0, 1 and 6 months and were seronegative at 6 months.
- Table B demonstrates that HPV 16 and HPV 18 provide statistically significant cross protection against the group of high risk cancer types 31,33,35,39,45,51,52,56,58,59, 66 and 68.
- Table C demonstrates that, except for the HPV- 18 related types (which show a very strong trend), there is statistically significant cross-protection against the groups of: HPV 31, 35, 58; HPV 31, 33, 35, 52, 58; and the 12 high risk (non HPV- 16/18) types evaluated. Further analysis was carried out on the specific cross protection against specific types.
- Vaccine efficacy was assessed against infections and diseases related to the 12 high risk cancer types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, HPV-16 phylogenetic-related types (the groups of; 31, 35, and 58; 31, 33, 35, 52 and 58) and HPV-18 phylogenetic related types (45 and 59).
- HPV-16 related HPV-16 phylogenetically related types 35, 31, 58 without considering other HPV types
- HPV-16 related* HPV-16 phylogenetically related types 35, 31, 58, 33, 52 without considering other HPV types
- HPV- 18 related HPV- 18 phylogenetically related types 45, 59 without considering other HPV types
- HPV-16 and/or HPV-18 related HPV-16 and/or HPV- 18 phylogenetically related types 35, 31, 58, 45, 59 without considering other HPV types
- HPV-16 and/or HPV-18 related* HPV-16 and/or HPV-18 phylogenetically related types 35, 31, 58,
- N number of subjects in specific cohort
- % Vaccine efficacy is 1 — (A/B) x 100, adjusted for relative size of vaccine and placebo group, wherein
- A % women in vaccine group with incident infection, persistent infection or cytological abnormality, as appropriate for the table
- B % women in placebo group with incident infection, persistent infection or cytological abnormality, as appropriate for the table.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007013475A MX2007013475A (en) | 2005-04-26 | 2006-04-24 | Vaccine. |
EP06753410A EP1879614A2 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
EA200702077A EA013325B1 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
AU2006239471A AU2006239471A1 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
BRPI0610396-0A BRPI0610396A2 (en) | 2005-04-26 | 2006-04-24 | multivalent hpv vaccine, methods to protect a patient against infection, to prevent or reduce the frequency of cytological abnormalities in a patient, to prevent the formation of histologically confirmed lesions and to manufacture the vaccine, and, uses of a composition, to a vaccine and a vaccine composition |
CA002606206A CA2606206A1 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
JP2008508138A JP2008539182A (en) | 2005-04-26 | 2006-04-24 | vaccine |
NO20075185A NO20075185L (en) | 2005-04-26 | 2007-10-11 | Vaccine |
IL186591A IL186591A0 (en) | 2005-04-26 | 2007-10-11 | Vaccine |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/114,301 | 2005-04-26 | ||
US11/114,301 US20050287161A1 (en) | 2002-12-20 | 2005-04-26 | Vaccine |
PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
EPPCT/EP2005/006461 | 2005-06-14 | ||
US11/367,601 | 2005-12-16 | ||
US11/367,601 US7858098B2 (en) | 2002-12-20 | 2005-12-16 | Vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006114273A2 true WO2006114273A2 (en) | 2006-11-02 |
WO2006114273A3 WO2006114273A3 (en) | 2007-03-15 |
Family
ID=37199195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/003809 WO2006114273A2 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1879614A2 (en) |
JP (1) | JP2008539182A (en) |
KR (1) | KR20080005583A (en) |
AR (1) | AR053715A1 (en) |
AU (1) | AU2006239471A1 (en) |
CA (1) | CA2606206A1 (en) |
EA (1) | EA013325B1 (en) |
MX (1) | MX2007013475A (en) |
NO (1) | NO20075185L (en) |
SG (1) | SG159529A1 (en) |
UY (1) | UY29499A1 (en) |
WO (1) | WO2006114273A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2444103B1 (en) * | 2009-06-19 | 2017-12-20 | Eyegene Inc. | Vaccine for cervical cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
EP1410805A1 (en) * | 1999-09-07 | 2004-04-21 | GlaxoSmithKline Biologicals S.A. | Vaccine against HPV |
WO2004056389A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
WO2005123125A1 (en) * | 2004-06-16 | 2005-12-29 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
-
2006
- 2006-04-24 EA EA200702077A patent/EA013325B1/en unknown
- 2006-04-24 JP JP2008508138A patent/JP2008539182A/en active Pending
- 2006-04-24 AU AU2006239471A patent/AU2006239471A1/en not_active Abandoned
- 2006-04-24 MX MX2007013475A patent/MX2007013475A/en unknown
- 2006-04-24 WO PCT/EP2006/003809 patent/WO2006114273A2/en active Application Filing
- 2006-04-24 KR KR1020077027492A patent/KR20080005583A/en not_active Application Discontinuation
- 2006-04-24 SG SG201000826-6A patent/SG159529A1/en unknown
- 2006-04-24 CA CA002606206A patent/CA2606206A1/en not_active Abandoned
- 2006-04-24 EP EP06753410A patent/EP1879614A2/en not_active Ceased
- 2006-04-24 AR ARP060101618A patent/AR053715A1/en not_active Application Discontinuation
- 2006-04-26 UY UY29499A patent/UY29499A1/en not_active Application Discontinuation
-
2007
- 2007-10-11 NO NO20075185A patent/NO20075185L/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1410805A1 (en) * | 1999-09-07 | 2004-04-21 | GlaxoSmithKline Biologicals S.A. | Vaccine against HPV |
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
WO2004056389A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
WO2005123125A1 (en) * | 2004-06-16 | 2005-12-29 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
Non-Patent Citations (7)
Title |
---|
GIROGLOU T ET AL: "Immunological analyses of human papillomavirus capsids" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 13-14, 2001, pages 1783-1793, XP002248440 ISSN: 0264-410X * |
GLAXOSMITHKLINE HPV VACCINE STUDY GROUP HARPER D M ET AL: "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial" LANCET THE, LANCET LIMITED. LONDON, GB, vol. 364, no. 9447, 13 November 2004 (2004-11-13), pages 1757-1765, XP004746625 ISSN: 0140-6736 cited in the application * |
REINIS MILAN: "Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL." CURRENT OPINION IN MOLECULAR THERAPEUTICS. APR 2004, vol. 6, no. 2, April 2004 (2004-04), pages 206-211, XP009056594 ISSN: 1464-8431 * |
RODEN R B S ET AL: "ASSESSMENT OF THE SEROLOGICAL RELATEDNESS OF GENITAL HUMAN PAPILLOMAVIRUSES BY HEMAGGLUTINATION INHIBITION" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 5, May 1996 (1996-05), pages 3298-3301, XP002946729 ISSN: 0022-538X * |
SAPP MARTIN ET AL: "Generation and applications of HPV pseudovirions using vaccinia virus." METHODS IN MOLECULAR MEDICINE. 2005, vol. 119, 2005, pages 463-482, XP009074697 ISSN: 1543-1894 * |
VILLA L L ET AL: "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial" LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 6, no. 5, 7 April 2005 (2005-04-07), pages 271-278, XP004870902 ISSN: 1470-2045 * |
WRIGHT T C ET AL: "Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts" VACCINE 21 AUG 2006 UNITED KINGDOM, vol. 24, no. SUPPL. 3, 21 August 2006 (2006-08-21), pages S251-S261, XP009074690 ISSN: 0264-410X * |
Also Published As
Publication number | Publication date |
---|---|
MX2007013475A (en) | 2008-04-02 |
EA200702077A1 (en) | 2008-04-28 |
WO2006114273A3 (en) | 2007-03-15 |
SG159529A1 (en) | 2010-03-30 |
AU2006239471A1 (en) | 2006-11-02 |
EP1879614A2 (en) | 2008-01-23 |
KR20080005583A (en) | 2008-01-14 |
CA2606206A1 (en) | 2006-11-02 |
JP2008539182A (en) | 2008-11-13 |
EA013325B1 (en) | 2010-04-30 |
NO20075185L (en) | 2008-01-25 |
AR053715A1 (en) | 2007-05-16 |
UY29499A1 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050287161A1 (en) | Vaccine | |
EP1758609B1 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
US20090181052A1 (en) | Vaccine | |
JP2012102132A (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
US7858098B2 (en) | Vaccine | |
US7758866B2 (en) | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 | |
EP1879614A2 (en) | Vaccine | |
CN101217975A (en) | Vaccine | |
BRPI0610032A2 (en) | use of a human papillomavirus l1 protein or immunogenic fragment thereof from a first type of hpv, vaccination program for protection against hiv infection and / or disease, method for preventing hpv infection and / or disease, vaccine composition and kit | |
BRPI0610396A2 (en) | multivalent hpv vaccine, methods to protect a patient against infection, to prevent or reduce the frequency of cytological abnormalities in a patient, to prevent the formation of histologically confirmed lesions and to manufacture the vaccine, and, uses of a composition, to a vaccine and a vaccine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006239471 Country of ref document: AU Ref document number: 186591 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 562525 Country of ref document: NZ Ref document number: 3971/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2606206 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008508138 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502366 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013475 Country of ref document: MX Ref document number: 200680014223.7 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07114258 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2006239471 Country of ref document: AU Date of ref document: 20060424 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006239471 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006753410 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000729 Country of ref document: DZ |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200702501 Country of ref document: VN Ref document number: 1020077027492 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200702077 Country of ref document: EA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06753410 Country of ref document: EP Kind code of ref document: A2 |
|
WWP | Wipo information: published in national office |
Ref document number: 2006753410 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0610396 Country of ref document: BR Kind code of ref document: A2 Effective date: 20071026 |